Results 91 to 100 of about 53,534 (265)
, 2009 The long-term efficacy of coronary or peripheral stenting is limited by in-stent restenosis (ISR), which occurs in 15 to 30% of patients and is attributed primarily to neointimal hyperplasia.
Bakhshi, R.
core
Portal Hypertension &Cirrhosis, EarlyView.As the hepatic venous pressure gradient (HVPG) remains the current gold standard for diagnosing portal hypertension in cirrhosis, its clinical application is limited by invasiveness, high cost, and restricted availability. Given the urgent need for noninvasive techniques to dynamically monitor portal vein pressure (PVP), contrast‐enhanced ...
Danping Huang +5 more
wiley +1 more source
, 2010 MD (Research)Background A near-patient test of responses to antiplatelet therapy would be of great value in percutaneous coronary intervention (PCI). However, at present, there are no widely accepted tests and varied definitions of “resistance”.
Hobson, Alex
core
, 2014 Values are expressed as number (%).EST = early stent thrombosis, LST = late stent thrombosis, VLST = very late stent thrombosis, DES = drug-eluting stents, BMS = bare-metal stents, ACS = acute coronary syndrome, and TIMI = thrombolysis in ...
Katsumi Inoue (585935) +9 more
core +1 more source
Portal Hypertension &Cirrhosis, EarlyView.This preclinical study evaluated a novel controlled‐expansion expanded polytetrafluoroethylene (ePTFE)‐covered transjugular intrahepatic portosystemic shunt (TIPS) stent in 11 swine, demonstrating 100% technical success, excellent deployability, and durable 6‐month angiographic patency without thrombosis, migration, fracture, or device‐related toxicity.
Yi Xiang +15 more
wiley +1 more source
Acta Medica Indonesiana, 2015 Antiplatelet is an important drug for patients with coronary heart disease undergoing drug-eluting stent implantation. Current guidelines recommend dual antiplatelet with aspirin and a P2Y12 inhibitor for at least 12 months.
Benedicta M Suwita +2 more
doaj +2 more sources
Coronary stent thrombosis in bare metal stents
Saudi Medical Journal, 2004 The incidence of coronary stent thrombosis has reduced with improved techniques and drugs. Nevertheless, clinical trials may not reflect real world practice due to the selective inclusion criteria, regional variations and more complex patients treated in day-to-day practice.
Waqar H, Ahmed, Khaled F, Al-Shaibi
openaire +2 more sources
Stent thrombosis of drug eluting stent: Pathological perspective
, 2011 SummaryAlthough, the first-generation drug eluting stents (DES) have significantly reduced rates of restenosis compared to bare metal stents (BMS), an increased risk of late stent thrombosis (LST) has emerged as a major concern.
Nakazawa, Gaku, Gaku Nakazawa
core +1 more source
Ten-Year Clinical Outcomes of Late-Acquired Stent Malapposition After Coronary Stent Implantation
, 2020 OBJECTIVE: The goal of this study was to determine the impact of late-acquired stent malapposition (LASM) on long-term clinical outcomes in patients treated with coronary stent implantation.
최동훈 +7 more
core +1 more source